Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2013

01-06-2013 | Research Article

Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan

Authors: Mohammad Ismail, Zafar Iqbal, Muhammad Bilal Khattak, Muhammad Imran Khan, Hassan Arsalan, Arshad Javaid, Qamar Gul, Faramoz Khan

Published in: International Journal of Clinical Pharmacy | Issue 3/2013

Login to get access

Abstract

Background Multiple drugs therapies may be the potential source of drug–drug interactions that can result in alteration of therapeutic response and/or increase untoward effects of many drugs. Objective To identify the frequency and levels of potential drug–drug interactions (pDDIs) in internal medicine wards and their association with patients’ age, gender, length of hospital stay and number of prescribed medications; and to describe management of frequently identified major or moderate pDDIs. Setting Internal medicine wards of two major tertiary care hospitals of Khyber Pakhtunkhwa, Pakistan. Method Micromedex Drug-Reax system was used to screen patient’s profiles for pDDIs. Logistic regression was applied to determine the odds ratio for specific risk factors of pDDIs i.e., age, gender, hospital-stay and number of medications. Main outcome measure Overall prevalence and prevalence of contraindicated, major, moderate and minor pDDIs; levels of pDDIs; frequently identified major or moderate interactions; and odds ratios for risk factors. Results Total, 188 interacting drug-combinations were identified that contributed to 675 pDDIs. Of 400 patients, 52.8 % patients were presented with at least one pDDI (overall prevalence), 21.3 % with at least one major-pDDI, and 44.3 % with at least one moderate-pDDI. Of 675 pDDIs, most were of moderate (63.6 %) or major severity (23 %); good (61.2 %) or fair (25.5 %) type of scientific evidence; and delayed onset (50.2 %). Most frequently identified major or moderate interactions resulted in 45.3 % of all pDDIs. Their potential adverse outcomes included hepatotoxicity, bleeding, ototoxicity, nephrotoxicity, hypoglycemia, hyperglycemia, risk of thrombosis, hypotension, cardiac arrhythmias and reduction in therapeutic-effectiveness. There was significant association of the occurrence of pDDIs with patients’ age of 60 years or more (OR = 2.1; 95 % CI = 1.3–3.3; p = 0.003), hospital stay of 6 days or longer (OR = 2.6; 95 % CI = 1.5–4.5; p = 0.001), and seven or more number of prescribed medications (OR = 5.9; 95 % CI = 3.6–9.6; p < 0.001). Conclusion The present study has recorded a high prevalence of pDDIs in internal medicine wards. Patients with old age, longer hospital stay and increased number of prescribed medications were at higher risk.
Literature
1.
go back to reference Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.PubMedCrossRef Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.PubMedCrossRef
2.
go back to reference Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMedCrossRef Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMedCrossRef
3.
go back to reference Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M, et al. Potential drug–drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci. 2010;32:187–93.PubMedCrossRef Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M, et al. Potential drug–drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci. 2010;32:187–93.PubMedCrossRef
4.
go back to reference Zwart-van-Rijkom JEF, Uijtendaal EV, Ten Berg MJ, Van Solinge WW, Egberts ACG. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68:187–93.PubMedCrossRef Zwart-van-Rijkom JEF, Uijtendaal EV, Ten Berg MJ, Van Solinge WW, Egberts ACG. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68:187–93.PubMedCrossRef
5.
go back to reference van den Bemt PM, Egberts AC, Lenderink AW, Verzijl JM, Simons KA, van der Pol WS, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62–6.PubMedCrossRef van den Bemt PM, Egberts AC, Lenderink AW, Verzijl JM, Simons KA, van der Pol WS, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62–6.PubMedCrossRef
6.
go back to reference Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedCrossRef Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedCrossRef
7.
go back to reference Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.PubMedCrossRef Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.PubMedCrossRef
8.
go back to reference Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19:413–20.PubMedCrossRef Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19:413–20.PubMedCrossRef
9.
go back to reference Anonymous. Report of the Health System Review Mission—Pakistan. Islamabad: World Health Organization, 2007. Anonymous. Report of the Health System Review Mission—Pakistan. Islamabad: World Health Organization, 2007.
10.
go back to reference Creese A, Gasman N, Mariko M. The world medicines situation: World Health Organization, 2004. Creese A, Gasman N, Mariko M. The world medicines situation: World Health Organization, 2004.
11.
go back to reference Ismail M, Iqbal Z, Hammad M, Ahsan S, Sheikh AL, Asim SM, et al. Drug utilization evaluation of piperacillin/tazobactam in a tertiary care teaching hospital. Healthmed. 2010;4:1044–55. Ismail M, Iqbal Z, Hammad M, Ahsan S, Sheikh AL, Asim SM, et al. Drug utilization evaluation of piperacillin/tazobactam in a tertiary care teaching hospital. Healthmed. 2010;4:1044–55.
13.
go back to reference Nishtar S. Pharmaceuticals–strategic considerations in health reforms in Pakistan. J Pak Med Assoc. 2006;56:S100–11.PubMed Nishtar S. Pharmaceuticals–strategic considerations in health reforms in Pakistan. J Pak Med Assoc. 2006;56:S100–11.PubMed
14.
go back to reference Babar ZU, Jamshed S. Social pharmacy strengthening clinical pharmacy: why pharmaceutical policy research is needed in Pakistan? Pharm World Sci. 2008;30:617–9.PubMedCrossRef Babar ZU, Jamshed S. Social pharmacy strengthening clinical pharmacy: why pharmaceutical policy research is needed in Pakistan? Pharm World Sci. 2008;30:617–9.PubMedCrossRef
15.
go back to reference Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug–drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res. 2012;11:289–96.CrossRef Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug–drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res. 2012;11:289–96.CrossRef
16.
go back to reference Micromedex Drug-Reax® System. [database on CD-ROM].Volume 150. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. 2011. Micromedex Drug-Reax® System. [database on CD-ROM].Volume 150. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. 2011.
17.
go back to reference Tatro D, editor. Drug interaction facts: facts and comparisons. St. Louis: Wolters Kluwer Health; 2009. Tatro D, editor. Drug interaction facts: facts and comparisons. St. Louis: Wolters Kluwer Health; 2009.
18.
go back to reference Ibanez A, Alcala M, Garcia J, Puche E. Drug-drug interactions in patients from an internal medicine service. Farm Hosp. 2008;32:293–7.PubMedCrossRef Ibanez A, Alcala M, Garcia J, Puche E. Drug-drug interactions in patients from an internal medicine service. Farm Hosp. 2008;32:293–7.PubMedCrossRef
19.
go back to reference Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.PubMed Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.PubMed
20.
go back to reference Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.PubMedCrossRef Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.PubMedCrossRef
21.
go back to reference Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.PubMedCrossRef Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.PubMedCrossRef
22.
go back to reference Doubova SV, Reyes-Morales H, Torres-Arreola LdP, Suarez-Orteg M. Potential drug–drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.CrossRef Doubova SV, Reyes-Morales H, Torres-Arreola LdP, Suarez-Orteg M. Potential drug–drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.CrossRef
23.
go back to reference Baxter K, editor. Stockley’s drug interactions. 9th ed. London: Pharmaceutical Press; 2010. Baxter K, editor. Stockley’s drug interactions. 9th ed. London: Pharmaceutical Press; 2010.
24.
go back to reference Hansten PD, Horn JR, editors. Drug interactions analysis and management: St. Louis: Wolters Kluwer Health Inc.; 2008. Hansten PD, Horn JR, editors. Drug interactions analysis and management: St. Louis: Wolters Kluwer Health Inc.; 2008.
Metadata
Title
Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan
Authors
Mohammad Ismail
Zafar Iqbal
Muhammad Bilal Khattak
Muhammad Imran Khan
Hassan Arsalan
Arshad Javaid
Qamar Gul
Faramoz Khan
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9764-1

Other articles of this Issue 3/2013

International Journal of Clinical Pharmacy 3/2013 Go to the issue